CFRX [NASD]
ContraFect Corporation
Index- P/E- EPS (ttm)-1.52 Insider Own4.87% Shs Outstand39.33M Perf Week4.82%
Market Cap5.98M Forward P/E- EPS next Y-1.26 Insider Trans0.00% Shs Float37.42M Perf Month-16.94%
Income-59.70M PEG- EPS next Q-0.29 Inst Own22.80% Short Float / Ratio1.20% / 0.50 Perf Quarter-37.60%
Sales- P/S- EPS this Y55.40% Inst Trans-61.13% Short Interest0.45M Perf Half Y-95.48%
Book/sh-0.08 P/B- EPS next Y21.30% ROA-128.00% Target Price3.67 Perf Year-95.25%
Cash/sh0.44 P/C0.34 EPS next 5Y12.70% ROE-267.90% 52W Range0.13 - 4.54 Perf YTD-94.30%
Dividend- P/FCF- EPS past 5Y42.10% ROI- 52W High-96.70% Beta0.32
Dividend %- Quick Ratio0.80 Sales past 5Y- Gross Margin- 52W Low17.65% ATR0.02
Employees38 Current Ratio0.80 Sales Q/Q- Oper. Margin- RSI (14)46.27 Volatility18.82% 14.70%
OptionableYes Debt/Eq- EPS Q/Q-222.50% Profit Margin- Rel Volume1.23 Prev Close0.16
ShortableYes LT Debt/Eq- EarningsNov 14 BMO Payout- Avg Volume887.64K Price0.15
Recom2.70 SMA20-0.20% SMA50-7.53% SMA200-91.92% Volume1,096,156 Change-4.82%
Jul-14-22Downgrade SVB Leerink Outperform → Mkt Perform $1
Jul-14-22Downgrade Cantor Fitzgerald Overweight → Neutral $15 → $1
Feb-02-22Upgrade WBB Securities Speculative Buy → Buy $6.50
Sep-09-21Initiated SVB Leerink Outperform $14
Jun-09-20Initiated Mizuho Buy $12
Jun-09-20Initiated Cantor Fitzgerald Overweight $15
Jul-28-16Initiated Piper Jaffray Overweight
Jul-22-16Downgrade Maxim Group Buy → Hold
Mar-15-16Reiterated Maxim Group Buy $8 → $7
Dec-31-15Reiterated Maxim Group Buy $16 → $9
Nov-30-22 08:34AM
Nov-28-22 08:00AM
Nov-22-22 05:21AM
Nov-14-22 08:00AM
Sep-12-22 07:32AM
07:30AM Loading…
07:30AM
Sep-01-22 07:15AM
Aug-15-22 01:08PM
08:30AM
08:25AM
Jul-14-22 10:05AM
Jul-13-22 04:05PM
Jun-27-22 12:02PM
Jun-14-22 07:30AM
Jun-06-22 07:30AM
07:20AM Loading…
May-26-22 07:20AM
May-23-22 08:00AM
May-20-22 08:30AM
May-16-22 07:30AM
Apr-27-22 09:00AM
08:00AM
Apr-18-22 07:30AM
Apr-04-22 07:15AM
Mar-24-22 08:00AM
Mar-21-22 08:30AM
Mar-02-22 04:20AM
Feb-10-22 07:30AM
Jan-06-22 04:05PM
Jan-01-22 07:23AM
Dec-20-21 09:00AM
05:52AM Loading…
Nov-30-21 05:52AM
Nov-15-21 07:30AM
Nov-09-21 07:30AM
Nov-01-21 07:11AM
Oct-26-21 07:30AM
Oct-12-21 06:26AM
Oct-04-21 09:00AM
Sep-29-21 07:30AM
Sep-22-21 07:30AM
Aug-30-21 07:18AM
Aug-13-21 07:30AM
Jul-27-21 10:27PM
Jul-26-21 05:53AM
Jul-19-21 07:31AM
07:30AM
Jun-28-21 02:54AM
Jun-24-21 10:42AM
Jun-17-21 07:31AM
07:30AM
May-26-21 07:30AM
May-24-21 08:19AM
May-14-21 07:30AM
May-03-21 07:30AM
Apr-26-21 07:30AM
Apr-15-21 06:30PM
Apr-09-21 06:40AM
Mar-30-21 07:30AM
03:00AM
Mar-22-21 04:05PM
Mar-17-21 04:01PM
Mar-16-21 06:27AM
Mar-12-21 07:36AM
Mar-11-21 04:05PM
Feb-11-21 07:00AM
Dec-30-20 12:55AM
Dec-11-20 05:59PM
Nov-24-20 06:56AM
Nov-13-20 08:33AM
Oct-31-20 08:00AM
Oct-26-20 07:00AM
Oct-01-20 07:31AM
Sep-09-20 07:30AM
Aug-25-20 07:30AM
Aug-19-20 05:50AM
Aug-14-20 07:30AM
Jul-20-20 07:30AM
Jul-03-20 08:48AM
Jun-18-20 10:56AM
Jun-17-20 07:30AM
Jun-15-20 07:30AM
Jun-10-20 01:46PM
May-29-20 06:43AM
May-26-20 07:30AM
May-22-20 07:10AM
May-21-20 10:59PM
04:09PM
May-15-20 07:30AM
May-11-20 07:30AM
Apr-21-20 07:00AM
Mar-30-20 05:00AM
Mar-23-20 06:15AM
Mar-21-20 09:01AM
Mar-18-20 07:00AM
Mar-04-20 07:00AM
Feb-24-20 07:00AM
Feb-18-20 03:45PM
03:10PM
11:25AM
Feb-04-20 07:00AM
Feb-03-20 07:00AM
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.